1 Canellos GP, "Treatment of Hodgkin lymphoma : a 50-year perspective" 32 : 163-168, 2014
2 Kuruvilla J, "Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma" 106 : 353-360, 2006
3 Mendler JH, "Salvage therapy in Hodgkin’s lymphoma" 14 : 425-432, 2009
4 Straus DJ, "Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine(ABVD)followed by radiation therapy(RT)versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease" 104 : 3483-3489, 2004
5 Younes A, "Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma" 30 : 2183-2189, 2012
6 Moskowitz AJ, "Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma" 31 : 456-460, 2013
7 Hertzberg MS, "Outpatient-based ifosfamide, carboplatin and etoposide(ICE)chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease" 14 (14): i11-i16, 2003
8 Armand P, "Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort single-arm phase II checkmate 205 trial" 36 : 1428-1439, 2018
9 Herrera AF, "Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma" 131 : 1183-1194, 2018
10 Santoro A, "Ifosfamide, gemcitabine, and vinorelbine : a new induction regimen for refractory and relapsed Hodgkin’s lymphoma" 92 : 35-41, 2007
1 Canellos GP, "Treatment of Hodgkin lymphoma : a 50-year perspective" 32 : 163-168, 2014
2 Kuruvilla J, "Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma" 106 : 353-360, 2006
3 Mendler JH, "Salvage therapy in Hodgkin’s lymphoma" 14 : 425-432, 2009
4 Straus DJ, "Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine(ABVD)followed by radiation therapy(RT)versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease" 104 : 3483-3489, 2004
5 Younes A, "Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma" 30 : 2183-2189, 2012
6 Moskowitz AJ, "Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma" 31 : 456-460, 2013
7 Hertzberg MS, "Outpatient-based ifosfamide, carboplatin and etoposide(ICE)chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease" 14 (14): i11-i16, 2003
8 Armand P, "Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort single-arm phase II checkmate 205 trial" 36 : 1428-1439, 2018
9 Herrera AF, "Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma" 131 : 1183-1194, 2018
10 Santoro A, "Ifosfamide, gemcitabine, and vinorelbine : a new induction regimen for refractory and relapsed Hodgkin’s lymphoma" 92 : 35-41, 2007
11 Bartlett NL, "Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin(GVD), a salvage regimen in relapsed Hodgkin’s lymphoma : CALGB 59804" 18 : 1071-1079, 2007
12 Gac AC, "Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases" 57 : 1149-1153, 2016
13 Abali H, "Comparison of ICE(ifosfamide-carboplatin-etoposide)versus DHAP(cytosine arabinoside-cisplatin-dexamethasone)as salvage chemotherapy in patients with relapsed or refractory lymphoma" 26 : 401-406, 2008
14 O’Connor OA, "Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma : an international, multicentre, single-arm, phase 1-2 trial" 19 : 257-266, 2018
15 Santoro A, "Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : final results of a multicenter phase II study" 34 : 3293-3299, 2016
16 Villa D, "Bendamustine and rituximab as induction therapy in both transplant-eligible and-ineligible patients with mantle cell lymphoma" 4 : 3486-3494, 2020
17 Moskowitz CH, "A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease : analysis by intent to treat and development of a prognostic model" 97 : 616-623, 2001